Cuba authorized emergency use of Soberana 02 and Soberana Plus





Aprueba el CECMED el autorizo de uso de emergencias a las Vacunas Cubanas SOBERANA 02 y SOBERANA Plus







IFV / Biocubafarma

Havana, August 21 (RHC)-- Cuba's regulatory authority approved on Friday the emergency use of the vaccine candidates Soberana 02 and Soberana Plus in its heterologous scheme against Covid-19.

The Finlay Vaccine Institute, leader of both projects, informed that after concluding a rigorous evaluation process, the State Control Agency of Medicines, Equipment and Medical Devices of the island (CECMED) gave the green light because the scheme complies with the established requirements and demonstrated 91.2 percent efficacy in the prevention of symptomatic forms of the disease.

CECMED had earlier approved on July 9 the emergency use of the anti-Covid-19 vaccine candidate Abdala from the Center for Genetic Engineering and Biotechnology (CIGB), which demonstrated 92.28 percent efficacy with its three-dose schedule during Phase III clinical trials.

With Friday's announcement, Cuba has three anti-COVID-19 vaccines, the only ones developed by a Latin American country.

 $\frac{https://www.radiohc.cu/en/noticias/nacionales/267637-cuba-authorized-emergency-use-of-soberana-02-and-soberana-plus}{soberana-plus}$



Radio Habana Cuba